Latest news

• Takeda and Zinfandel abandon Alzheimer’s drug

  Pioglitazone failed to show therapeutic improvements in late-stage testing. A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics after it ... Takeda joined forces with Zinfandel on

• Takeda continues Actos resurrection as Alzheimer's drug

  Late-stage trial will see if pioglitazone can delay disease progression. Takeda and partner Zinfandel Pharma have started a phase III trial of pioglitazone in people at risk of developing the ... Earlier studies of pioglitazone in symptomatic AD patients

• Non-amyloid therapies emerging for Alzheimer's at AAIC

  Takeda and Zinfandel Pharmaceuticals highlighted a new approach to identifying individuals who are at risk of developing Alzheimer's dementia which could be used to support clinical trials of early treatments.

• Creative partnerships

  Preclinical. 100. Zinfandel Pharma/Takeda. TOMM40 assay, biomarker for risk of developing Alzheimer's disease.

• Takeda signs Alzheimer's deal for Actos

  Under the partnership deal, Takeda has licensed the rights to an assay from the small US company Zinfandel Pharmaceuticals that it plans to use to identify high-risk older adults who ... The biomarker is being developed by Zinfandel to identify healthy